Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2003

View Archived Issues

Novel therapeutic strategies for diabetes

Janssen describes novel inhibitors of TNF-alpha and/or IL-12 production

Arpida prepares and tests novel antibacterial agents

Aventis presents new MCH receptor modulators with anorectic activity

Dual NK1 antagonists/5-HT reuptake inhibitors and their use reported by GSK

New glucokinase activators in early development at AstraZeneca

Oxytocin agonists with utility in erectile dysfunction claimed by Ferring

GSK scientists identify new Lp-PLA2 inhibitors for use in atherosclerosis therapy

Novel DNA protein kinase inhibitors discovered by Cancer Research Technology

New beta3-adrenoceptor agonists discovered at Lilly

Zonagen terminates Lavipharm merger agreement

Xenogen and Morphochem to develop novel compounds against bacterial biofilms

DOV Pharmaceutical reports on past four months

Hexvix improves treatment of bladder cancer patients

E.U. Erbitux filing remains on track following data review

FDA advisory committee sets May date for review of Xolair BLA

IL-10 gene therapy prolongs islet graft survival and inhibits diabetes recurrence in mice

Bay-41-2272 as an alternative to nitrate therapy for CHF and related disorders

CVT-4325, a new FOX inhibitor, induces a metabolic shift to glucose utilization in rat hearts

Selective inhibitor of Itk designed at BMS as lead compound for T-cell-mediated disorders

New series with strong activity against PTP1B presented at ACS meeting

Nonimidazole H3 receptor antagonist A-320436 characterized in preclinical experiments

Regeneron and Novartis to codevelop IL-1 Trap for RA

Johnson & Johnson completes acquisition of 3-DP

Normalization of lipid profiles in hypercholesterolemic rabbits on JTT-705

Chronic YM-598 restores myocardial energy metabolism to normal in CHF rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...